Silo Pharma Buys Qwikagents.ai, Targets $47–$53B AI Agent Market
Silo Pharma acquired Qwikagents.ai and formed a dedicated AI subsidiary to enter the AI agent market projected at $47–$53 billion by 2030 with 43–50% annual growth. The company retains focus on advancing its SPC-15 PTSD program toward an IND submission and first-in-human Phase 1 trial.
1. Strategic Acquisition of Qwikagents.ai
In April 2026, Silo Pharma acquired the assets of Qwikagents.ai, an AI platform for autonomous agents, marking entry into a second business line focused on AI infrastructure. The acquisition grants Silo proprietary smart-routing technology for research, content generation, scheduling, and workflow automation tasks.
2. AI Market Opportunity
Industry projections forecast the AI agent market reaching $47–$53 billion by 2030, with annual growth rates of 43%–50%, driven by demand for scalable autonomous solutions. This market presents multi-billion dollar revenue potential as businesses adopt AI agents for digital transformation.
3. Formation of Dedicated AI Subsidiary
Silo Pharma established a dedicated subsidiary to operate Qwikagents.ai and future AI infrastructure investments, streamlining governance and resource allocation. This structure segregates AI operations to facilitate targeted development or acquisition of complementary technologies.
4. Continued Biopharmaceutical Pipeline Progress
Despite strategic diversification, Silo remains committed to its core biopharmaceutical pipeline, preparing an IND submission for SPC-15 targeting PTSD and planning a first-in-human Phase 1 trial. Other programs include SP-26 for chronic pain and preclinical assets for Alzheimer’s disease.